Skip to main content

Table 1 The general characteristic of the included RCTs

From: Denosumab compared to bisphosphonates to treat postmenopausal osteoporosis: a meta-analysis

Author

Sample (n)

Mean age (year)

Intervention

Comparison

Duration (month)

Outcomes

Study

Country

Intervention

Comparison

Intervention

Comparison

Beck 2008 [11]

USA

39

38

63

63

Sc denosumab injections (60 mg Q6M)

Oral alendronate 70 mg once weekly

24

56

RCTs

Lewiecki 2007 [12]

USA

319

47

62.3

62.8

Sc denosumab injections (60 mg Q6M)

Oral alendronate 70 mg once weekly

24

1

RCTs

McClung 2006 [13]

USA

47

47

63.1

62.8

Sc denosumab injections (60 mg Q6M)

Oral alendronate 70 mg once weekly

12

123,467

RCTs

Brown 2009 [14]

Spain

594

595

64.1

64.6

Sc denosumab injections (60 mg Q6M)

Oral alendronate 70 mg once weekly

12

1,234,567

RCTs

Kendler 2010 [15]

USA

253

251

66.9

68.2

Sc denosumab injections (60 mg Q6M)

Oral alendronate 70 mg once weekly

12

234,567

RCTs

Freemantle 2012 [16]

UK

126

124

65.1

65.3

Sc denosumab injections (60 mg Q6M)

Oral alendronate 70 mg once weekly

24

2345

RCTs

Kendler 2011 [17]

Canada

253

251

66.9

68.2

Sc denosumab injections (60 mg Q6M)

Oral alendronate 70 mg once weekly

12

56

RCTs

Recknor 2013 [18]

USA

417

416

67.2

66.2

Sc denosumab injections (60 mg Q6M)

Oral ibandronate 150 mg once month

12

12,346

RCTs

Roux 2014 [19]

France

422

402

67.8

67.7

Sc denosumab injections (60 mg Q6M)

Oral risedronate 150 mg once month

12

123,456

RCTs

Miller 2016 [20]

USA

320

320

65.9

66.1

Sc denosumab injections (60 mg Q6M)

intravenous zoledronic acid 5 mg once year

12

123,457

RCTs

Seeman 2010 [21]

Australia

83

82

60.3

60.7

Sc denosumab injections (60 mg Q6M)

oral alendronate 70 mg once weekly

12

23

RCTs

  1. 1, risk of fracture; 2, AEs, 3 withdrawn due to AEs; 4, change in total hip BMD; 5, change in femoral neck BMD; 6, change in lumbar spine BMD; 7, change in one-third radius BMD